MICHAEL P KOSTY
Allopathic & Osteopathic Physicians|Internal Medicine|Hematology & Oncology LA JOLLA, CA NPI 1801857099
Browse related groups: Allopathic & Osteopathic Physicians|Internal Medicine|Hematology & Oncology CA Daiichi Sankyo Inc. All categories
General Payments — all program years on this page
$92,166.65
- Category: General Payments
- Program years: PY2018–2024
- Record count: 905
- As of (CMS publication): 2026-01-23
Latest program year (PY2024): $3,466.61 across 49 records · disputed records: 0
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How this figure is calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
Latest program year (PY2024) · sorted by reported total.
| Nature of payment | Amount | Records |
|---|---|---|
| Consulting Fee | $2,350.00 | 2 |
| Food and Beverage | $1,116.61 | 47 |
By paying entity
Latest program year (PY2024) · sorted by reported total.
| Paying entity | Amount | Records |
|---|---|---|
| Daiichi Sankyo Inc. | $2,374.48 | 4 |
| Gilead Sciences, Inc. | $109.33 | 4 |
| EISAI INC. | $93.94 | 4 |
| GlaxoSmithKline, LLC. | $69.31 | 3 |
| Janssen Biotech, Inc. | $57.06 | 2 |
| Kite Pharma, Inc. | $53.98 | 2 |
| E.R. Squibb & Sons, L.L.C. | $50.38 | 2 |
| Merck Sharp & Dohme Corporation | $48.03 | 3 |
| Exelixis Inc. | $46.76 | 2 |
| GENZYME CORPORATION | $38.39 | 1 |
| Tempus AI, Inc | $38.35 | 2 |
| ABBVIE INC. | $37.10 | 2 |
| Celgene Corporation | $36.80 | 1 |
| PharmaEssentia USA Corporation | $34.83 | 1 |
| Acerta Pharma LLC | $34.51 | 2 |
| SpringWorks Therapeutics, Inc. | $34.24 | 1 |
| Bayer HealthCare Pharmaceuticals Inc. | $33.54 | 1 |
| Coherus Biosciences Inc. | $31.16 | 1 |
| BeiGene USA, Inc. | $26.83 | 1 |
| Astellas Pharma US Inc | $26.31 | 1 |
| ARRAY BIOPHARMA INC | $26.21 | 1 |
| Genmab U.S., Inc. | $23.62 | 1 |
| Regeneron Healthcare Solutions, Inc. | $23.46 | 1 |
| Kyowa Kirin, Inc. | $22.92 | 1 |
| ACCORD HEALTHCARE, INC. | $22.44 | 1 |
| Alexion Pharmaceuticals, Inc. | $20.61 | 1 |
| Takeda Pharmaceuticals U.S.A., Inc. | $19.86 | 1 |
| CSL Behring | $16.55 | 1 |
| EMD Serono, Inc. | $15.61 | 1 |
By program year
Records — PY2024 (49)
Provenance & corrections
- Dataset: CMS Open Payments — General Payments
- Source: CMS Open Payments dataset (bulk file)
- Publisher of source data: Centers for Medicare & Medicaid Services
- Generated from: OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.